国: ニュージーランド
言語: 英語
ソース: Ministry for Primary Industries
imidapril hcl
Ethical Agents Veterinary Marketing Limited
imidapril hcl
imidapril hcl 170 g/kg
Cardiovascular agent
ACVM Registered
2005-07-22
PRILIUM ® 150mg Imidapril HCL Oral powder for reconstitution 170 g/kg as freeze dried powder or 5 g/L reconstituted solution Indications In dogs: treatment of heart failure of stages II, III and IV according to the NYHA classification, caused by mitral regurgitation or by dilated cardiomyopathy. The product may be combined, if necessary, with diuretics such as furosemide and/or with digoxin. Imidapril is a new angiotensin-converting enzyme (ACE) inhibitor. Pharmacodynamic properties: Imidapril is a pro-drug, which is hydrolysed in vivo to form an active metabolite, imidaprilat. Imidaprilat inhibits the angiotensin-converting enzyme (ACE). This enzyme catalyses the conversion of angiotensin I to angiotensin II in the blood plasma and tissues and inhibits the breakdown of bradykinin. As angiotensin II has a potent vasoconstrictive action, while bradykinin is a vasodilator, the reduced formation of angiotensin II and the inhibition of bradykinin breakdown lead to vasodilation. In addition, plasma angiotensin II induces the release of aldosterone in the renin-angiotensin system. Imidaprilat therefore reduces the secretion of aldosterone. This leads to an increase in the serum potassium concentration and a decrease in the serum sodium concentration. So, imidapril reduces heart preload and postload, and decreases blood pressure without any compensatory increase in the heart rate arising. Pharmacokinetic properties: Following oral administration in the dog, imidapril is rapidly absorbed by the gastrointestinal tract and reaches its maximum plasma concentration within less than one hour. The half-life of imidapril is about 2 hours. Imidapril is mainly hydrolysed in the liver and kidney to its active Veterinary Pharmaceuticals 70204 LURE Cedex (France) metabolite, imidaprilat. Maximum plasma concentrations of imidaprilat are reached within about 5 hours and decline with a half-life of more than 10 hours. The bioavailability of imidapril and imidaprilat is decreased by the joint administration of food. The prot 完全なドキュメントを読む